Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Indonesian Mega-Farm Drives Surge in Deforestation - 2NASA set for first crewed moon return in over half a century
- 3Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- 4Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- 5Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- Beyond oil: The crucial exports blocked by Hormuz closure
- Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- People with depression can treat themselves at home with new device
- Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- Air superiority and long-range strikes: what China's war games say about how it might assault Taiwan
- Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Humpback whale stranded on Germany's Baltic coast frees itself
